Pitavastatin Enhanced BMP-2 and Osteocalcin Expression by Inhibition of Rho-Associated Kinase in Human Osteoblasts

Rodan, 2000, Therapeutic approaches to bone diseases, Science, 289, 1508, 10.1126/science.289.5484.1508

Mundy, 1999, What can we learn from bone biology for the treatment for osteoporosis, Osteoporos. Int., 9, S40, 10.1007/PL00004160

Rosen, 2001, Anabolic therapy for osteoporosis, J. Clin. Endocrinol. Metab., 86, 957, 10.1210/jcem.86.3.7366

Riley, 1996, Bone morphogenetic protein-2: Biology and applications, Clin. Orthop., 324, 39, 10.1097/00003086-199603000-00006

Mundy, 1999, Stimulation of bone formation in vitro and in rodents by statins, Science, 286, 1946, 10.1126/science.286.5446.1946

Chan, 2000, Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women, Lancet, 355, 2185, 10.1016/S0140-6736(00)02400-4

Meier, 2000, HMG-CoA reductase inhibitors and the risk of fractures, JAMA, 283, 3205, 10.1001/jama.283.24.3205

Wang, 2000, HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients, JAMA, 283, 3211, 10.1001/jama.283.24.3211

Laufs, 1997, Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase, J. Biol. Chem., 272, 31725, 10.1074/jbc.272.50.31725

Kureishi, 2000, The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals, Nat. Med., 6, 1004, 10.1038/79510

Laufs, 1999, 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing Rho GTPase-induced down-regulation of p27(Kip1), J. Biol. Chem., 274, 21926, 10.1074/jbc.274.31.21926

Kwak, 2000, Statins as a newly recognized type of immunomodulator, Nat. Med., 6, 1399, 10.1038/82219

Goldstein, 1990, Regulation of the mevalonate pathway, Nature, 343, 425, 10.1038/343425a0

Laufs, 2000, Direct vascular effects of HMG-CoA reductase inhibitors, Trends Cardiovasc. Med., 10, 143, 10.1016/S1050-1738(00)00044-X

Van Aelst, 1997, Rho GTPases and signaling networks, Genes. Dev., 11, 2295, 10.1101/gad.11.18.2295

Hall, 1998, Rho GTPases and the actin cytoskeleton, Science, 279, 509, 10.1126/science.279.5350.509

Fukata, 2001, Rho-Rho-kinase pathway in smooth muscle contraction and cytoskeletal reorganization of non-muscle cells, Trends Pharmacol. Sci., 22, 32, 10.1016/S0165-6147(00)01596-0

Aoki, 1997, Pharmacological profile of a novel synthetic inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, Arzneimittelforschung, 47, 904

Tanaka, 1996, 1,25-Dihydroxyvitamin D3 enhances the enzymatic activity and expression of the messenger ribonucleic acid for aromatase cytochrome P450 synergistically with dexamethasone depending on the vitamin D receptor level in cultured human osteoblasts, Endocrinology, 137, 1860, 10.1210/endo.137.5.8612525

Ohnaka, 2000, Induction of cyclooxygenase-2 by angiotensin II in cultured rat vascular smooth muscle cells, Hypertension, 35, 68, 10.1161/01.HYP.35.1.68

Mu, 1998, Low level of glucocorticoid receptor messenger ribonucleic acid in pituitary adenomas manifesting Cushing's disease with resistance to a high dose-dexamethasone suppression test, Clin. Endocrinol. (Oxf.), 49, 301, 10.1046/j.1365-2265.1998.00520.x

Yokoi, 1993, Non-radioisotopic quantitative RT-PCR to detect changes in mRNA levels during early mouse embryo development, Biochem. Biophys. Res. Commun., 195, 769, 10.1006/bbrc.1993.2112

Gohla, 1998, The G-protein G13 but not G12 mediates signaling from lysophosphatidic acid receptor via epidermal growth factor receptor to Rho, J. Biol. Chem., 273, 4653, 10.1074/jbc.273.8.4653

Kawano, 1999, Phosphorylation of myosin-binding subunit (MBS) of myosin phosphatase by Rho-kinase in vivo, J. Cell. Biol., 147, 1023, 10.1083/jcb.147.5.1023

Shimokawa, 1999, Rho-kinase-mediated pathway induces enhanced myosin light chain phosphorylations in a swine model of coronary artery spasm, Cardiovasc. Res., 43, 1029, 10.1016/S0008-6363(99)00144-3

Sugiyama, 2000, Compactin and simvastatin, but not pravastatin, induce bone morphogenetic protein-2 in human osteosarcoma cells, Biochem. Biophys. Res. Commun., 271, 688, 10.1006/bbrc.2000.2697

Maeda, 2001, Simvastatin promotes osteoblast differentiation and mineralization in MC3T3-E1 cells, Biochem. Biophys. Res. Commun., 280, 874, 10.1006/bbrc.2000.4232

Laufs, 1998, Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase, J. Biol. Chem., 273, 24266, 10.1074/jbc.273.37.24266

Lian, 1999, Regulated expression of the bone-specific osteocalcin gene by vitamins and hormones, Vitam. Horm., 55, 443, 10.1016/S0083-6729(08)60941-3

Canalis, 1996, Mechanisms of glucocorticoid action in bone: Implications to glucocorticoid-induced osteoporosis, J. Clin. Endocrinol. Metab., 81, 3441

Manelli, 2000, Glucocorticoid-induced osteoporosis, Trends Endocrinol. Metab., 11, 79, 10.1016/S1043-2760(00)00234-4